Parkman Healthcare Partners LLC
Long book
$964.6M
Q1 2026
Positions
89
Top-10 weight
35%
concentration
Last quarter
+17.7%
SPY +14.8%
Turnover
38%
of book per quarter
Strategy in plain words
auto-generated from filingsParkman Healthcare Partners LLC is an institutional manager, specialised in healthcare (96% of the long book), running a $964.6M US long book across 89 positions.
The portfolio is moderately concentrated (top 10 ≈ 35% of the book). The portfolio is actively managed, with meaningful quarterly turnover. Current anchor positions: STRYKER CORP, DEXCOM INC, KALVISTA PHARMACEUTICALS INC, INSULET CORP, ELI LILLY & CO.
Over the last 9 quarters its long book ran on average 2.5pp per quarter behind the S&P 500, beating the index in 4 of 9 quarters. Signal value of individual moves is limited — treat changes as weak evidence.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-4.5%
Q2 2024
+7.7%
Q3 2024
-7.8%
Q4 2024
-5.9%
Q1 2025
-2.1%
Q2 2025
+16.5%
Q3 2025
+9.8%
Q4 2025
-13.4%
Q1 2026
+17.7%
Sector allocation
Healthcare 92%
Other 4%
Consumer discretionary 1%
Technology 1%
Materials 1%
Services media 0%
Long book by quarter
What does Parkman Healthcare own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| SYK STRYKER CORP | Healthcare | 154.8K | $50.9M | 5.3% | +46.7% |
| DXCM DEXCOM INC | Healthcare | 689.8K | $43.3M | 4.5% | +17.4% |
| 4XC1 KALVISTA PHARMACEUTICALS INC | — | 1.8M | $36.9M | 3.8% | +3.8% |
| PODD INSULET CORP | Healthcare | 156.6K | $32.9M | 3.4% | +11.1% |
| LLY ELI LILLY & CO | Healthcare | 34.6K | $31.8M | 3.3% | New |
| PTCT PTC THERAPEUTICS INC | Healthcare | 431.4K | $29.4M | 3.0% | +169.3% |
| XENE XENON PHARMACEUTICALS INC | Healthcare | 497.0K | $28.9M | 3.0% | +222.4% |
| BSX BOSTON SCIENTIFIC CORP | Healthcare | 448.8K | $28.2M | 2.9% | -10.3% |
| CVS CVS HEALTH CORP | Healthcare | 387.3K | $27.8M | 2.9% | -14.0% |
| RCUS ARCUS BIOSCIENCES INC | Healthcare | 1.2M | $26.1M | 2.7% | +24.6% |
| LIVN LIVANOVA PLC | Healthcare | 404.0K | $25.7M | 2.7% | -1.7% |
| ZBH ZIMMER BIOMET HOLDINGS INC | Healthcare | 269.6K | $24.4M | 2.5% | +78.5% |
| MBX MBX BIOSCIENCES INC | Healthcare | 800.0K | $23.9M | 2.5% | -9.7% |
| ANIP ANI PHARMACEUTICALS INC | Healthcare | 280.6K | $21.6M | 2.2% | +93.5% |
| SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 901.5K | $21.1M | 2.2% | +57.1% |
| QGEN QIAGEN N.V. | Healthcare | 500.0K | $20.0M | 2.1% | New |
| NVST ENVISTA HOLDINGS CORP | Healthcare | 711.7K | $18.1M | 1.9% | New |
| EYPT EYEPOINT INC | Healthcare | 1.4M | $17.5M | 1.8% | +24.5% |
| ABBV ABBVIE INC | Healthcare | 75.0K | $16.3M | 1.7% | New |
| BCRX BIOCRYST PHARMACEUTICALS INC | Healthcare | 1.7M | $16.3M | 1.7% | +89.8% |
| IQV IQVIA HOLDINGS INC | Healthcare | 86.7K | $14.8M | 1.5% | +146.1% |
| AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 403.5K | $13.7M | 1.4% | +305.1% |
| ILMN ILLUMINA INC | Healthcare | 110.4K | $13.6M | 1.4% | New |
| EW EDWARDS LIFESCIENCES CORP | Healthcare | 167.2K | $13.4M | 1.4% | +10.7% |
| NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 99.1K | $13.1M | 1.4% | -13.6% |
| KNSA KINIKSA PHARMACEUTICALS INTE | Healthcare | 259.2K | $12.5M | 1.3% | -61.0% |
| ASMB ASSEMBLY BIOSCIENCES INC | Healthcare | 411.2K | $11.4M | 1.2% | +64.9% |
| MCK MCKESSON CORP | Consumer discretionary | 12.7K | $11.0M | 1.1% | -65.1% |
| STOK STOKE THERAPEUTICS INC | Healthcare | 336.5K | $11.0M | 1.1% | -21.8% |
| VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 557.9K | $10.9M | 1.1% | -29.2% |
| WAY WAYSTAR HOLDING CORP | Technology | 443.1K | $10.7M | 1.1% | +20.1% |
| MLYS MINERALYS THERAPEUTICS INC | Healthcare | 380.1K | $10.3M | 1.1% | -7.3% |
| EWTX EDGEWISE THERAPEUTICS INC | Healthcare | 322.8K | $10.2M | 1.1% | -24.5% |
| XERS XERIS BIOPHARMA HOLDINGS INC | Healthcare | 1.7M | $10.0M | 1.0% | +1.8% |
| THC TENET HEALTHCARE CORP | Healthcare | 50.1K | $9.5M | 1.0% | -17.2% |
| AORT ARTIVION INC | Healthcare | 252.0K | $9.2M | 1.0% | +15.2% |
| NUVL NUVALENT INC-A | Healthcare | 88.1K | $9.0M | 0.9% | -25.8% |
| ATEC ALPHATEC HOLDINGS INC | Healthcare | 823.8K | $9.0M | 0.9% | +197.2% |
| ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 26.9K | $8.9M | 0.9% | -43.6% |
| AXGN AXOGEN INC | Healthcare | 268.2K | $8.9M | 0.9% | +7.1% |
| IMNM IMMUNOME INC | Healthcare | 403.5K | $8.8M | 0.9% | +45.2% |
| AMLX AMYLYX PHARMACEUTICALS INC | Healthcare | 621.5K | $8.6M | 0.9% | +62.8% |
| IDXX IDEXX LABORATORIES INC | Materials | 15.0K | $8.4M | 0.9% | New |
| WAT WATERS CORP | Healthcare | 26.4K | $7.9M | 0.8% | -36.9% |
| ADPT ADAPTIVE BIOTECHNOLOGIES | Healthcare | 551.8K | $7.7M | 0.8% | +37.4% |
| UPB UPSTREAM BIO INC | Healthcare | 786.8K | $7.1M | 0.7% | -5.7% |
| ERAS ERASCA INC | Healthcare | 406.7K | $6.6M | 0.7% | New |
| APGE APOGEE THERAPEUTICS INC | Healthcare | 77.7K | $6.5M | 0.7% | -40.3% |
| COO COOPER COS INC/THE | Healthcare | 89.9K | $6.4M | 0.7% | -28.3% |
| ABSI ABSCI CORP | Healthcare | 1.9M | $5.6M | 0.6% | +27.8% |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 15, 2026 | 90 | $969.6M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 17, 2026 | 100 | $1.05B | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 91 | $958.7M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 88 | $870.1M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 91 | $843.1M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 89 | $750.9M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 93 | $783.4M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 14, 2024 | 90 | $746.6M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 15, 2024 | 99 | $815.0M | canonical | SEC ↗ |